Clinical Trials | October 01, 2025
Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
The new site enables end-to-end production of viral vector gene therapies
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Prior to this appointment, he served as Vice-Chancellor of Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur,
Cagrilintide represents a novel approach to obesity management
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Subscribe To Our Newsletter & Stay Updated
